PhaseRx, Inc. (PZRXQ)
- Previous Close
0.0002 - Open
0.0002 - Bid --
- Ask --
- Day's Range
0.0002 - 0.0002 - 52 Week Range
0.0002 - 0.0002 - Volume
250 - Avg. Volume
0 - Market Cap (intraday)
15,197 - Beta (5Y Monthly) 1.66
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1300 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
PhaseRx, Inc., a biopharmaceutical company, engages in developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy. The company develops its products based on its proprietary Hybrid mRNA technology platform, which allows the synthesis of missing enzyme inside the cell. Its therapeutic urea cycle disorder programs under development include PRX-OTC to treat ornithine transcarbamylase deficiency; PRX-ASL to treat argininosuccinate lyase deficiency; and PRX-ASS1 to treat argininosuccinate synthetase deficiency. The company was incorporated in 2006 and is headquartered in Seattle, Washington.
Recent News: PZRXQ
View MorePerformance Overview: PZRXQ
Trailing total returns as of 5/21/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PZRXQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PZRXQ
View MoreValuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-64.20%
Return on Equity (ttm)
-228.17%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-13.89M
Diluted EPS (ttm)
-0.1300
Balance Sheet and Cash Flow
Total Cash (mrq)
5.26M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-7.68M